Science and Research

Uni Köln Guidance: GUIDANCE – A multicenter phase II trial of maintenance durvalumab and olaparib after standard 1st line treatment (car-boplatin or cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small cell lung cancer (SCLC)

Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, dur-valumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)

Study details
Study-ID: NCT06419179, 2024-512373-27-00
Study-ID: NCT06419179, 2024-512373-27-00
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - public
Funding: Externally - public
DZL Participating Sites: TLRC
DZL Participating Sites: TLRC
Start Date: 09.10.2024
Completion Date: 31.12.2026
Status: Enrolling by invitation
Status: Enrolling by invitation
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.